Would you consider offering immunotherapy +/- olaparib to a patient with early-stage endometrial carcinoma for whom you are recommending adjuvant chemotherapy based on improved outcomes seen in RUBY/DUO-E/NRG-GY018?

I hesitate to offer the chemo/IO combination to patients with stage I disease as this is likely an overtreatment. The majority of the patients who require chemotherapy for stage I disease are those with serous and carcinosarcoma histology. Most of those patients are not even MMRd. It is unclear what...

Because high risk Stage I patients were not included in these trials (serous, carcinsarcoma, clear cell, mixed histologies), I don't typically recommend the addition of IO to chemotherapy for early stage disease. We will likely see this data for the dMMR early stage patients in future trials.